Abemaciclib (LY2835219) più Fulvestrant rispetto a placebo più Fulvestrant nel carcinoma mammario trattato in precedenza (postMONARCH)
postMONARCH: uno studio di fase 3 randomizzato, in doppio cieco, controllato con placebo per confrontare l'efficacia di Abemaciclib Plus Fulvestrant rispetto a Placebo Plus Fulvestrant in partecipanti con carcinoma mammario HR+, HER2-, avanzato o metastatico in seguito a progressione su un inibitore CDK4 e 6 ed endocrino Terapia
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Accesso esteso
Accesso esteso
Approvato
- Disponibile: l'accesso esteso è attualmente disponibile per questo trattamento sperimentale e i pazienti che non partecipano allo studio clinico potrebbero essere in grado di accedere al farmaco, al biologico o al dispositivo medico in fase di studio.
- Non più disponibile: l'accesso esteso era disponibile per questo intervento in precedenza, ma non è attualmente disponibile e non sarà disponibile in futuro.
- Temporaneamente non disponibile: l'accesso esteso non è attualmente disponibile per questo intervento, ma dovrebbe esserlo in futuro.
- Approvato per il marketing: l'intervento è stato approvato dalla Food and Drug Administration degli Stati Uniti per l'uso da parte del pubblico.
Contatti e Sedi
Luoghi di studio
-
-
-
San Juan, Argentina, 5400
- CER San Juan
-
-
Buenos Air
-
Buenos Aires, Buenos Air, Argentina, C1426ABP
- Fundación Respirar
-
Ciudad Autónoma de Buenos Aire, Buenos Air, Argentina, C1027AAP
- Centro de Investigaciones Metabólicas (CINME)
-
-
Buenos Aires F.D.
-
CABA, Buenos Aires F.D., Argentina, 1125
- Fundación Cenit Para La Investigación En Neurociencias
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentina, 5800
- Instituto Médico Río Cuarto
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentina, 4000
- Centro Medico San Roque
-
-
-
-
-
Namur, Belgio, 5000
- CHU UCL Namur/Site Sainte Elisabeth
-
-
Antwerpen
-
Brasschaat, Antwerpen, Belgio, 2930
- Algemeen Ziekenhuis klina
-
-
Limburg
-
Hasselt, Limburg, Belgio, 3500
- Jessa Ziekenhuis
-
-
-
-
-
Hradec Králové, Cechia, 500 05
- Fakultni nemocnice Hradec Kralove
-
-
Pardubice Region
-
Pardubice, Pardubice Region, Cechia, 53203
- Multiscan
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Corea del Sud, 13620
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], Corea del Sud, 02841
- Korea University Anam Hospital
-
Seoul, Seoul-teukbyeolsi [Seoul], Corea del Sud, 08308
- Korea University Guro Hospital
-
-
Taegu-Kwangyǒkshi
-
Daegu, Taegu-Kwangyǒkshi, Corea del Sud, 41404
- Kyungpook National University Chilgok Hospital
-
-
-
-
Capital Region
-
Copenhagen, Capital Region, Danimarca, 2730
- Herlev and Gentofte Hospital
-
-
Central Jutland
-
Herning, Central Jutland, Danimarca, 7400
- Regionshospitalet Gødstrup
-
-
-
-
Aquitaine
-
Bordeaux, Aquitaine, Francia, 33076
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
-
-
Finistère
-
Brest, Finistère, Francia, 29609
- CHRU de Brest
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Francia, 44277
- Hôpital privé du Confluent SAS
-
-
Vendée
-
La Roche-sur-Yon, Vendée, Francia, 85000
- CHD Vendee
-
-
-
-
-
Thessaloniki, Grecia, 546 45
- Euromedica General Clinic of Thessaloniki
-
-
Achaḯa
-
Pátrai, Achaḯa, Grecia, 26504
- University Hospital of Patras
-
-
Attikí
-
Athens, Attikí, Grecia, 115 28
- Alexandra Hospital
-
-
Irakleío
-
Heraklion, Irakleío, Grecia, 711 10
- University General Hospital of Heraklion
-
-
-
-
Central District
-
Kfar Saba, Central District, Israele, 4428164
- Meir Medical Center
-
Petah Tikva, Central District, Israele
- Rabin Medical Center
-
Ramat Gan, Central District, Israele, 5265601
- Sheba Medical Center
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israele, 9112001
- Hadassah Medical Center
-
-
Southern District
-
Beersheba, Southern District, Israele, 8400000
- Soroka Medical Center
-
-
Tell Abīb
-
Tel Aviv, Tell Abīb, Israele, 6423906
- Sourasky Medical Center
-
-
-
-
-
Bari, Italia, 70124
- Instituto Tumori Giovanni Paolo II
-
Grosseto, Italia, 58100
- Ospedale Misericordia di Grosseto
-
Milan, Italia, 20132
- Ospedale San Raffaele
-
Viterbo, Italia, 01100
- ASL Viterbo Ospedale Belcolle
-
-
Catania
-
Misterbianco, Catania, Italia, 95045
- Humanitas Istituto Clinico Catanese
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italia, 47014
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
-
-
Friuli Venezia Giulia
-
Udine, Friuli Venezia Giulia, Italia, 33100
- P.O. "S. Maria della Misericordia" Azienda Sanitaria Universitaria Friuli Centrale
-
-
-
-
Estado de Baja California
-
Mexicali, Estado de Baja California, Messico, 21200
- Centro de Investigacion en Artritis y Osteoporosis SC
-
Tijuana, Estado de Baja California, Messico, 22010
- COI Tijuana - Centro Oncológico Internacional
-
-
Jalisco
-
Guadalajara, Jalisco, Messico, 45647
- Centro Oncológico Internacional (COI)
-
-
Nuevo León
-
Monterrey, Nuevo León, Messico, 64060
- Centro Regiomontano de Investigación
-
-
San Luis Potosí
-
San Luis Potosí City, San Luis Potosí, Messico, 78209
- Oncologico Potosino, S.C.
-
-
-
-
Masovian Voivodeship
-
Otwock, Masovian Voivodeship, Polonia, 05-400
- Europejskie Centrum Zdrowia - Oddzial Onkologii
-
-
Opole Voivodeship
-
Opole, Opole Voivodeship, Polonia, 45-060
- Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
-
-
-
-
-
Badajoz, Spagna, 06006
- Hospital Infanta Cristina
-
Madrid, Spagna, 28009
- Hospital General Universitario Gregorio Marañon
-
Toledo, Spagna, 45007
- Hospital Universitario de Toledo
-
-
A Coruña [La Coruña]
-
A Coruña, A Coruña [La Coruña], Spagna, 15006
- CHUAC-Hospital Teresa Herrera
-
-
Balears [Baleares]
-
Palma, Balears [Baleares], Spagna, 07120
- Hospital Universitari Son Espases
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], Spagna, 08003
- Parc de Salut Mar - Hospital del Mar
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Spagna, 08036
- Hospital Clínic de Barcelona
-
-
Murcia, Región de
-
El Palmar, Murcia, Región de, Spagna, 30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Málaga
-
Málaga, Málaga, Spagna, 29011
- H.R.U Málaga - Hospital Materno-infantil
-
-
Navarre
-
Pamplona, Navarre, Spagna, 31009
- Complejo Hospitalario de Navarra
-
-
Tarragona [Tarragona]
-
Reus, Tarragona [Tarragona], Spagna, 43204
- Hospital Universitari Sant Joan de Reus
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Spagna, 46017
- Hospital Universitario Doctor Peset
-
-
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85004
- St. Joseph's Hospital and Medical Center
-
-
Arkansas
-
Springdale, Arkansas, Stati Uniti, 72762
- Highlands Oncology Group
-
-
California
-
Fullerton, California, Stati Uniti, 92835
- Providence Medical Foundation
-
Los Alamitos, California, Stati Uniti, 90720
- Cancer and Blood Specialty Clinic
-
Los Angeles, California, Stati Uniti, 90033
- Keck School of Medicine of USC
-
Los Angeles, California, Stati Uniti, 90024
- TRIO-US (Translational Research in Oncology-US)
-
Santa Monica, California, Stati Uniti, 90404
- UCLA Hematology/Oncology - Parkside
-
Sylmar, California, Stati Uniti, 91342
- Olive View-UCLA Medical Center
-
Torrance, California, Stati Uniti, 90505
- Torrance Memorial Physician Network / Cancer Care
-
Whittier, California, Stati Uniti, 90602
- PIH Health Hematology Medical Oncology
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80220
- Rocky Mountain Cancer Center - Hale Parkway
-
-
Florida
-
Fort Myers, Florida, Stati Uniti, 33901-8101
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
Hollywood, Florida, Stati Uniti, 33024
- Millennium Oncology Research Clinic
-
Miami, Florida, Stati Uniti, 33136
- University of Miami Hospital and Clinics, Sylvester Cancer Center
-
Pensacola, Florida, Stati Uniti, 32503
- Woodlands Medical Specialists, PA
-
Sarasota, Florida, Stati Uniti, 34232
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
West Palm Beach, Florida, Stati Uniti, 33401
- Florida Cancer Specialists EAST/Sarah Cannon Research Institute/SCRI
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Winship Cancer Institute, Emory University
-
Gainesville, Georgia, Stati Uniti, 30501
- Northeast Georgia Medical Center
-
Macon, Georgia, Stati Uniti, 31201
- Central Georgia Cancer Care
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96826
- Kapiolani Medical Center for Women and Children
-
-
Illinois
-
Harvey, Illinois, Stati Uniti, 60426
- Ingalls Memorial Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70809
- Hematology Oncology Clinic- Baton Rouge/Sarah Cannon Research Institute/SCRI
-
Lake Charles, Louisiana, Stati Uniti, 70601
- Clinical Trials of SWLA
-
-
Maine
-
Lewiston, Maine, Stati Uniti, 04240
- Central Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21237
- Mfsmc-Hjwci
-
Clinton, Maryland, Stati Uniti, 20735
- Maryland Oncology Hematology, P.A. - Clinton
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Stati Uniti, 02215
- Dana Farber Cancer Institute
-
Danvers, Massachusetts, Stati Uniti, 01923
- MGH Northshore Cancer Center
-
Fairhaven, Massachusetts, Stati Uniti, 02719
- Southcoast Centers for Cancer Care
-
Foxborough, Massachusetts, Stati Uniti, 02035
- Dana-Farber Cancer Institute - Foxborough
-
Methuen, Massachusetts, Stati Uniti, 01844
- Dana Farber Cancer Center Merrimack Valley
-
Milford, Massachusetts, Stati Uniti, 01757
- Dana Farber Cancer Institute
-
Newton, Massachusetts, Stati Uniti, 02462
- Mass General Cancer Center
-
South Weymouth, Massachusetts, Stati Uniti, 02190
- Dana Farber Cancer Institute
-
Worcester, Massachusetts, Stati Uniti, 01606
- Reliant Medical Group
-
-
Montana
-
Billings, Montana, Stati Uniti, 59102
- St. Vincent Frontier Cancer Center
-
-
New Hampshire
-
Londonderry, New Hampshire, Stati Uniti, 03053
- Dana Farber Cancer Center Londonderry
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- University of New Mexico Comprehensive Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02906
- Lifespan Cancer Institute
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37404
- Tennessee Oncology-Chattanooga /Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, Stati Uniti, 37203
- Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, Stati Uniti, 37203
- Tennessee Oncology-Nashville/Sarah Cannon Research Institute/SCRI
-
-
Texas
-
Bedford, Texas, Stati Uniti, 76022
- Texas Oncology - Bedford
-
Denton, Texas, Stati Uniti, 76201
- Texas Oncology - Denton
-
El Paso, Texas, Stati Uniti, 79902
- Texas Oncology, P.A.
-
Houston, Texas, Stati Uniti, 77030-4009
- University of Texas MD Anderson Cancer Center
-
McKinney, Texas, Stati Uniti, 75071
- Texas Oncology - McKinney
-
McKinney, Texas, Stati Uniti, 75071
- Woodlands Medical Specialists, PA
-
Mesquite, Texas, Stati Uniti, 75150
- Woodlands Medical Specialists, PA
-
Plano, Texas, Stati Uniti, 75093
- Texas Oncology-Plano West
-
Plano, Texas, Stati Uniti, 75075-7787
- Texas Oncology - Plano East
-
San Antonio, Texas, Stati Uniti, 78229
- Mays Cancer Center
-
The Woodlands, Texas, Stati Uniti, 77380
- US Oncology
-
Tyler, Texas, Stati Uniti, 75702
- Texas Oncology - Tyler Cancer Center
-
-
Utah
-
Murray, Utah, Stati Uniti, 84107
- Intermountain Medical Center
-
St. George, Utah, Stati Uniti, 84790
- Intermountain Healthcare - St. George
-
-
Vermont
-
Burlington, Vermont, Stati Uniti, 05401
- The University of Vermont Medical Center Inc.
-
-
Virginia
-
Winchester, Virginia, Stati Uniti, 22601
- Shenandoah Oncology, P.C.
-
-
-
-
Stockholms
-
Stockholm, Stockholms, Svezia, 171 76
- Karolinska Universitetssjukhuset Solna
-
-
Örebro Län [se-18]
-
Örebro, Örebro Län [se-18], Svezia, 701 85
- Universitetssjukhuset Örebro
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Kaohsiung Medical University Hospital
-
New Taipei City, Taiwan, 231
- Taipei Tzu Chi General Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 10449
- Mackay Memorial Hospital
-
Taoyuan, Taiwan, 333
- Chang Gung Medical Foundation-Linkou Branch
-
-
Tainan
-
Tainan, Tainan, Taiwan, 71004
- Chi Mei Medical Center
-
-
-
-
-
Adana, Turchia (Türkiye), 01370
- Adana City Hospital
-
Ankara, Turchia (Türkiye), 06520
- Memorial Ankara Hastanesi
-
Ankara, Turchia (Türkiye), 06010
- Ankara Gülhane Eitim ve Aratrma Hastanesi
-
Diyarbakır, Turchia (Türkiye), 21200
- Dicle Üniversitesi
-
Edirne, Turchia (Türkiye), 22030
- Trakya University
-
Istanbul, Turchia (Türkiye), 34722
- TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
-
Malatya, Turchia (Türkiye), 44280
- İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi
-
-
Konya
-
Meram, Konya, Turchia (Türkiye), 42080
- Necmettin Erbakan Meram Medical Fac.
-
-
İzmir
-
Cordaleo, İzmir, Turchia (Türkiye), 009035575
- Izmir Medical Park Hospital
-
-
-
-
-
Budapest, Ungheria, 1122
- Országos Onkológiai Intézet
-
Budapest, Ungheria, 1062
- Magyar Honvedseg Egeszsegugyi Kozpont
-
-
Bács-Kiskun county
-
Kecskemét, Bács-Kiskun county, Ungheria, 6000
- Bacs-Kiskun Megyei Korhaz
-
-
Győr-Moson-Sopron
-
Győr, Győr-Moson-Sopron, Ungheria, 9024
- Petz Aladar Egyetemi Oktato Korhaz
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer
-
Have radiologic evidence of disease progression or recurrence either
- On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
- On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer
-
Must be deemed appropriate for treatment with ET
-
If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression
-
Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)
-
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)
-
Have adequate renal, hematologic, and hepatic organ function
-
Must be able to swallow capsules/tablets
Exclusion Criteria:
- Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
- Have symptomatic or untreated central nervous system metastasis
- Have received any systemic therapy between disease recurrence/progression and study screening
- Have received more than 1 line of therapy for advanced or metastatic disease.
- Have received prior chemotherapy for metastatic breast cancer (MBC)
- Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm A: Abemaciclib plus Fulvestrant
Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered orally. Administered IM. |
|
Comparatore attivo: Arm B: Placebo plus Fulvestrant
Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered IM. Administered orally. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-Free Survival (PFS)
Lasso di tempo: Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Lasso di tempo: Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
|
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
Lasso di tempo: Randomization until measured progressive disease (Up to 22 Months)
|
ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. |
Randomization until measured progressive disease (Up to 22 Months)
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Pubblicazioni e link utili
Pubblicazioni generali
- Zapatero-Solana E, Ding Y, Pulliam N, de Dios A, Ortiz-Ruiz MJ, Lallena MJ. Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. Int J Mol Sci. 2025 Mar 14;26(6):2643. doi: 10.3390/ijms26062643.
- Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Munoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18.
- Kalinsky K, Wander SA, Hamilton E, Graff SL, Jeselsohn R, Park KH, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Ravenberg E, Amdur S, Litchfield LM, Bianchini G. Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. Ann Oncol. 2026 Oct 24:S0923-7534(26)08075-0. doi: 10.1016/j.annonc.2026.10.1283. Online ahead of print.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie per sede
- Neoplasie
- Processi neoplastici
- Malattie della pelle
- Malattie del seno
- Condizioni patologiche, segni e sintomi
- Malattie della pelle e del tessuto connettivo
- Neoplasie mammarie
- Metastasi neoplastica
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Composti policiclici
- Steroidi
- Composti anelli fusi
- Estradiolo
- Estrene
- Estrane
- Congeneri di estradiolo
- Ormoni steroidi gonadali
- Ormoni gonadali
- Fulvestrant
- Abemaciclib
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 18238
- I3Y-MC-JPEF (Altro identificatore: Eli Lilly and Company)
- 2021-002301-10 (Numero EudraCT)
- 2023-506771-10-00 (Altro identificatore: EU Trial Number)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Periodo di condivisione IPD
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Criteri di accesso alla condivisione IPD
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .